1. Home
  2. KPLT vs NSRX Comparison

KPLT vs NSRX Comparison

Compare KPLT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$6.24

Market Cap

34.3M

ML Signal

HOLD

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.35

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
NSRX
Founded
2012
2019
Country
United States
Israel
Employees
87
7
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
38.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KPLT
NSRX
Price
$6.24
$3.35
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$19.67
AVG Volume (30 Days)
6.1K
12.5K
Earning Date
05-07-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.62
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$1.98
52 Week High
$24.15
$9.99

Technical Indicators

Market Signals
Indicator
KPLT
NSRX
Relative Strength Index (RSI) 38.00 56.51
Support Level $5.89 $2.83
Resistance Level $6.79 $3.60
Average True Range (ATR) 0.49 0.21
MACD -0.11 0.04
Stochastic Oscillator 17.37 65.73

Price Performance

Historical Comparison
KPLT
NSRX

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: